Neurocrine Biosciences (NASDAQ:NBIX) Shares Down 9.3% on Analyst Downgrade

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down 9.3% during trading on Thursday after Needham & Company LLC lowered their price target on the stock from $187.00 to $185.00. Needham & Company LLC currently has a buy rating on the stock. Neurocrine Biosciences traded as low as $123.00 and last traded at $124.6040. 801,498 shares changed hands during mid-day trading, a decline of 27% from the average session volume of 1,094,193 shares. The stock had previously closed at $137.44.

Several other research analysts have also recently issued reports on NBIX. Morgan Stanley reissued an “equal weight” rating and set a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a report on Thursday, January 8th. JPMorgan Chase & Co. reduced their price target on shares of Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating on the stock in a report on Monday, January 12th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Piper Sandler upped their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Fifteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $176.28.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director George J. Morrow sold 15,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total value of $2,150,550.00. Following the completion of the sale, the director directly owned 7,068 shares in the company, valued at approximately $1,013,339.16. This represents a 67.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $159.65, for a total value of $698,628.40. Following the transaction, the insider owned 43,405 shares in the company, valued at approximately $6,929,608.25. This represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 61,966 shares of company stock valued at $8,625,166 in the last quarter. Company insiders own 4.80% of the company’s stock.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts largely maintain Buy ratings and high price targets, citing a durable Ingrezza franchise and upside from the emerging Crenessity program — Bank of America reaffirmed a Buy and a $190 target. TipRanks: BofA Buy & $190 PT
• Positive Sentiment: Quarterly revenue showed strong year-over-year growth and the company provided full‑year 2026 Ingrezza net sales guidance of $2.7–$2.8 billion, supporting the view of a durable commercial franchise. PR Newswire: Q4 results & 2026 guidance
• Neutral Sentiment: Some analysts trimmed price targets slightly (Needham: $187→$185; HC Wainwright: $198→$192) but kept Buy ratings — the cuts are modest and leaves consensus targets well above the current share price. Benzinga: PT adjustments
• Negative Sentiment: EPS missed expectations: the company reported $1.88 EPS for Q4 versus the consensus (~$2.36), a material shortfall that pressured the stock. MarketBeat: Q4 EPS miss
• Negative Sentiment: Market reaction was negative after the print: multiple reports note the stock fell on the Q4 results, and outlets flagged near-term cost pressures and cautious 2026 guidance commentary. Investing.com: cautious 2026 guidance
• Negative Sentiment: Insider selling and noted institutional portfolio moves were highlighted in post‑earnings coverage, which can add to near‑term pressure on sentiment. Quiver Quant: stock reaction & insider trading

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently added to or reduced their stakes in NBIX. Dodge & Cox raised its position in shares of Neurocrine Biosciences by 0.6% in the 2nd quarter. Dodge & Cox now owns 5,566,814 shares of the company’s stock valued at $699,693,000 after purchasing an additional 32,190 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Neurocrine Biosciences by 11.0% in the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after buying an additional 468,405 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after buying an additional 1,263,633 shares during the last quarter. Geode Capital Management LLC raised its holdings in Neurocrine Biosciences by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after acquiring an additional 34,457 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock valued at $178,248,000 after acquiring an additional 88,522 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 9.3%

The stock’s 50 day simple moving average is $141.39 and its 200 day simple moving average is $140.58. The stock has a market capitalization of $12.42 billion, a P/E ratio of 29.81, a P/E/G ratio of 0.65 and a beta of 0.31.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.